Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Regulatory Material +

Jushi Holdings Inc. Applauds President Trump and Administration for Delivering on Cannabis Rescheduling to Schedule III under the Controlled Substances Act

Regulatory Shift Removes Tax Penalty, Debt Overhang Persists

By The Northwire Desk — AI Analysis Apr 23, 2026 · 09:43 JUSH · 0.84 Jushi Holdings Inc.
Executive Summary
  • Headline: Jushi Holdings Inc. Applauds President Trump and Administration for Delivering on Cannabis Rescheduling to Schedule III under the Controlled Substances Act.
  • Date: April 23, 2026.
  • Core Event: The U.S. administration has finalized the rescheduling of cannabis from Schedule I to Schedule III.
  • Implications:
    • Removes significant tax penalties (specifically Section 280E restrictions on deductions).
    • Advances medical research and patient access.
    • Does not equate to full federal legalization but modernizes policy.
  • Management Quote: CEO Jim Cacioppo states this acknowledges clinical evidence that cannabis should be regulated, not prohibited.
Material Impact
  • Tax Impact: The shift from Schedule I to III is the most significant financial catalyst for U.S. MSOs in years. It allows companies to deduct ordinary business expenses against revenue, which was previously prohibited under Section 280E for Schedule I substances.
  • Financial Projection: Jushi reported FY2025 Adjusted EBITDA of $50.3M but a Net Loss of $68.6M. The gap is largely driven by taxes and interest. Rescheduling could convert the net loss into profitability in the next fiscal year, assuming tax rates normalize.
  • Market Sentiment: This validates the long-term investment thesis for U.S. cannabis operators that have been penalized by federal policy despite state-level legality.
  • Critical View: Schedule III still subjects cannabis to FDA oversight and does not guarantee full banking normalization or interstate commerce immediately. The market may have partially priced in regulatory relief, limiting immediate upside compared to a full descheduling event.
JUSH · Price
Company Overview
  • Business Model: Multi-State Operator (MSO) focused on retail dispensaries, cultivation, and branded products across eight states.
  • Flagship Brand: Beyond Hello™ (dispensaries), Jushi-branded products (flower, vapes, edibles).
  • Footprint: 42 operating dispensaries as of December 31, 2025, in Illinois, Pennsylvania, Virginia, Ohio, Florida, New Jersey, and others.
  • Expansion: Opened eight new stores in FY2025; first New Jersey location opened. Virginia adult-use market expected to launch sales January 1, 2027.
Read the original news release →

More from Jushi Holdings Inc.

Jun 30, 2026 · 08:30

Virginia adult-use legalization unlocks long-term growth runway, but near-term financials remain flat as market discounts distant catalysts.

Production / Operations Jun 24, 2026 · 16:15

Redomiciliation approved, but margin compression and debt service weigh on sentiment

Regulatory May 28, 2026 · 08:00

Jushi Submits DEA Registration Following Cannabis Rescheduling; Stock Holds Steady

Regulatory May 12, 2026 · 16:05

Jushi Stabilizes Balance Sheet with High-Cost Debt as Margin Expansion Offsets Persistent Net Losses

Earnings May 08, 2026 · 16:05

Jushi Holdings CEO Increases Stake Following Cannabis Rescheduling; Nevada Move Nears

Other Apr 24, 2026 · 08:30

Jushi Aligns Corporate Domicile with U.S. Operations Amidst Regulatory Shift

Other